Embodiments of the present disclosure describe substituted phenethylamine derivatives, compositions comprising the substituted phenethylamine derivatives, methods of making the substituted phenethylamine derivatives, and methods of using the phenethylamine derivatives, and the like. Exemplary compounds of the present disclosure include compounds of the formula (I) and (II):

##STR00001##

wherein X, R.sup.a, R.sup.b, R.sup.c, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined elsewhere.

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof

##STR00001##

wherein Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.

Described herein are ?.sup.9-THC prodrugs, methods of making ?.sup.9-THC prodrugs, formulations comprising ?.sup.9-THC prodrugs and methods of using ?.sup.9-THC. One embodiment described herein relates to the transdermal administration of a ?.sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Described herein are ?.sup.9-THC prodrugs, methods of making ?.sup.9-THC prodrugs, formulations comprising ?.sup.9-THC prodrugs and methods of using ?.sup.9-THC. One embodiment described herein relates to the transdermal administration of a ?.sup.9-THC prodrug for treating and preventing diseases and/or disorders.

This invention is related to a compound with the structural formula (I)

##STR00001## wherein, R1, and R2 are independently selected from the group consisting of C.sub.1-C.sub.6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH.sub.2NHR.sub.9, C(?O)YR.sub.10, CH2OH

##STR00002##